Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam sodium injection in Chinese adults with carbapenem-resistant gram-negative infections
CTR20230851Phase 4Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2023
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftazidime + avibactam in Gram-negative bacterial infection, hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Intra-abdominal infection (IAI), bloodstream infection (BSI), sponsored by Qilu Pharmaceutical. Started Jun 2023; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
Gram-negative bacterial infectionhospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)bloodstream infection (BSI)
Beyond the preview
Go deeper on CTR20230851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230851.